Keith Stauffer

Cigna Holding Co. engages in the provision of medical, dental, disability, life and accident insurance, and related products and services to businesses, governmental and non-governmental organizations, and individuals, through its subsidiaries. The company was founded in 1981 and is headquartered in Bloomfield, CT.

Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA.

Molecular Sensing Plc develops software and tools for DNA and RNA analysis. The company is headquartered in Melksham, the United Kingdom.

Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ.

Inform Diagnostics, Inc. provides pathology diagnostic services. It offers subspecialty anatomic pathology in the fields of breast health, dermatology, gastroenterology, hematology, and urology. The company was founded by David D. Halbert and Harold Roe in 1996 and is headquartered in Irving, TX.

Horstmann Controls Ltd. is a British company. The private company is located in the UK.

BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million.

Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The company is based in St. Peter Port, UK.

BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993.

Willow Laboratories & Medical Center provides clinical and forensic toxicology laboratories services. The company was founded in 1995 by Brian J. Strasnick and is headquartered in Lynn, MA.

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Day Zero Diagnostics, Inc. operates as an infectious disease diagnostic firm. It develops technologies to modernize the treatment for infectious diseases. The company was founded by Jong Leeis, Miriam Huntley, Doug Kwon, Melis Anahtar, and Dougal Maclaurin and is headquartered in Boston, MA.

QuantuMDx Group Ltd. develops devices for diagnostics detection. The firm offers DNA-XT, Under The Tree Diagnostics, Q-POC, and Internet of Life. The company was founded by Jonathan O'Halloran, Elaine Warburton, and Julian Warburton in March 2008 and is headquartered in Newcastle upon Tyne, the United Kingdom.

PathAI, Inc. provides artificial intelligence powered technology for the pathology laboratory. It offers research and drug development, clinical and global health solutions. The firm specializes in pathology, digital pathology, oncology, immune-oncology, auto immune disease, neurodegenerative disease, companion diagnostics, precision medicine, solutions, research and development and computational pathology. The company was founded by Andrew H. Beck and Aditya Khosla in 2016 and is headquartered in Cambridge, MA.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Team Better, LLC develops mobile software applications. The private company is based in Encinitas.

Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Mirvie, Inc. provides precise, actionable, non-invasive tests for maternal-fetal health. The company is headquartered in South San Francisco, CA.

Strong Room Technology Pty Ltd. provides electronic controlled drug register (ECDR), opioid replacement therapy (OTP/ORT), staged supply, e-prescribing, administration reporting, pharmacy ward theatre configuration & notification, and enterprise reporting. The company is based in Melbourne, Australia. The Australian company's system uses human-centric design principles and has adjustable modules for medication management based on context and care provider needs. The company prioritizes user feedback in product development to ensure that their products, tools, systems, and platform align with customer needs and preferences through customer co-creation. The company was founded in 2017 by Mark Feldschuh, Max Mito, Chris Durre, Kieran Start. Max Mito has been the CEO since 2017.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.